NGAL, with its rapid response to kidney injury and its tubular secretion, may prove to be a valuable biomarker for early detection of AKI, aiding in early diagnosis, monitoring, and potentially guiding treatment decisions in critically ill patients. The gene discussed is LCN2; the disease is acute kidney injury.